The Segal Cancer Proteomics Centre (SCPC) applies state-of-the-art quantitative mass spectrometry-based proteomics and metabolomics methods for research, provides services to the academic, pharmaceutical and biotechnology groups, and translates quantitative mass spectrometry assays to the clinic. The Jewish General Hospital Proteomics Centre encompasses the Segal Cancer Proteomics Centre (SCPC) and the Warren Y. Soper Program in Translational Proteomics.
Basic Research:
路 (Fundamental) method development
路 MultiOMICS for personalized medicine
路 Proteogeonomics
Translational Research:
路 Targeted MS assays for the clinic
路 Immuno MALDI
Services:
路 Identification of PTMs
路 Relative quantitative proteomics and phosphoproteomics
路 Targeted quantitative mass spectrometry
路 MultiOMICS
路 Protein-protein interactions
路 Metabolomics
路 Large scale quantitative analysis
Our technologies can be applied to a wide range of samples, from purified proteins and protein complexes to biofluids, cells, biopsies and FFPE tissues, requiring only minimal sample amounts (e.g. few 碌L of blood; few 碌g of total protein from cells and tissues).
Websites:听
Contact:
Dr. Ren茅 P. Zahedi, Associate Director
Segal Cancer Proteomics Centre
Lady Davis Institute
Jewish General Hospital
3755 C么te Ste-Catherine Road, room E-615
Montreal, Quebec H3T 1E2
Tel: 514-340-8222 Ext. 27885
rene.zahedi [at] ladydavis.ca (Email)
Dr. Christoph Borchers, Director
Segal Cancer Proteomics Centre
Lady Davis Institute
Jewish General Hospital
3755 C么te Ste-Catherine Road, room E-615
Montreal, Quebec H3T 1E2
Tel: 514-340-8222 Ext. 27885
christoph [at] proteincentre.com (Email)
